$DNA Income Statement | Understand Stock

$DNA

$11.27 +$1.25 (12.48%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenue
Cell Engineering
Service
Foundry Revenue
Product
Total revenue

Costs and operating expenses:
Cost of revenue
Service
Product
Other
Research and development
Impairment of lease assets
Goodwill impairment
Restructuring charges
Total operating expenses
Loss from operations
Other income (expense):
Interest income
Interest expense
Loss on equity method investments
Loss on investments
Loss on deconsolidation of subsidiaries
Change in fair value of warrant liabilities
Gain on settlement of partnership agreement
Other (expense) income, net
Total other (expense) income, net
Total other income (expense)

Loss before income taxes
Income tax benefit
Loss attributable to non-controlling interest
Net loss
Other comprehensive income (loss):
Foreign currency translation adjustment
Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary
Unrealized gain on available-for-sale securities
Total other comprehensive income (loss)
Comprehensive loss
Earnings Per Share
Basic (in dollars per share)
Diluted (in dollars per share)
Weighted Average Number of Shares Outstanding, Basic
Basic (in shares)
Weighted average common shares outstanding, diluted (in shares)

Comments